---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122816"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:39:04.784183+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma Q3 net loss $19.2M; cash runway to end 2026; Phase 2 enrollment on track

## Summary
- Net loss $19.2M in Q3 2024 vs $16.6M Q3 2023; R&D spend rose to $16.9M on trial costs.
- Cash $197.9M at Sep 30, 2024; provides expected runway to end of 2026.
- Phase 2 PYNNACLE trial enrollment on track; >75% sites activated; interim analysis expected mid-2025.
- Investigator-initiated Phase 1b of rezatapopt in AML/MDS with MD Anderson and MSKCC; enrollment planned Q1 2025.
- Discontinued Phase 1b combination arm with pembrolizumab due to dose-limiting toxicities and limited benefit.

## SEC filing metadata
- accession: 0000950170-24-122816
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000095017024122816/0000950170-24-122816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000095017024122816/pmvp-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122816
- JSON: https://secwatch.observer/filing/0000950170-24-122816.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122816.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.